SAN
DIEGO, March 24, 2022 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced a global
collaboration and license agreement with Chugai Pharmaceutical Co.,
Ltd. that gives exclusive access to Halozyme's ENHANZE®
drug delivery technology, recombinant human hyaluronidase PH20
enzyme (rHuPH20), for an undisclosed target. Chugai intends
to explore the potential use of ENHANZE® for a Chugai
drug candidate.
Under the terms of the agreement, Chugai will make an upfront
payment of $25 million to Halozyme
and is obligated to make potential future payments of up to
$160 million in the aggregate,
subject to achievement of specified development, regulatory and
sales-based milestones. Halozyme will also be entitled to
receive royalties on sales of commercialized medicines using the
ENHANZE® technology.
"We are thrilled to announce our latest collaboration and
license agreement for ENHANZE® and look forward to
working closely with Chugai to advance this program," said Dr.
Helen Torley, president and chief
executive officer. "Our twelfth collaboration demonstrates the
continued strong interest in providing patients with the option to
receive treatment through a subcutaneous injection. This new
collaboration further expands the number of Wave 5 potential launch
programs, which we project will extend the revenue duration of our
ENHANZE® franchise."
Chugai represents Halozyme's twelfth global collaboration and
license partner for the ENHANZE® technology. These
collaborations cover more than 60 therapeutic targets and include
five commercialized products to date.
About ENHANZE® Technology
Halozyme's proprietary ENHANZE® drug-delivery
technology is based on its patented recombinant human hyaluronidase
enzyme (rHuPH20). rHuPH20 has been shown to remove
traditional limitations on the volume of biologics that can be
delivered subcutaneously (just under the skin). By using
rHuPH20, some biologics and compounds that are administered
intravenously may instead be delivered subcutaneously.
ENHANZE® may also benefit subcutaneous
biologics by reducing the need for multiple injections. This
delivery has been shown in studies to reduce health care
practitioner time required for administration and shorten time for
drug administration.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. Halozyme advises and
supports its biopharmaceutical partners in key aspects of new drug
development with the goal of improving patients' lives while
helping its partners achieve global commercial success. As the
innovators of the ENHANZE® technology, which can reduce
hours-long treatments to a matter of minutes, Halozyme's
commercially-validated solution has touched more than 600,000
patient lives in post-marketing use via five commercialized
products across more than 100 global markets. Halozyme and its
world-class partners are currently advancing multiple therapeutic
programs intended to deliver innovative therapies, with the
potential to improve the lives of patients around the globe.
Halozyme's proprietary enzyme rHuPH20 forms the basis of the
ENHANZE® technology and is used to facilitate the
delivery of injected drugs and fluids, potentially reducing the
treatment burden of other drugs to patients. Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Baxalta, Pfizer, AbbVie,
Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon
Therapeutics, ViiV Healthcare and Chugai Pharmaceutical. Halozyme
derives revenues from these collaborations in the form of
milestones and royalties as the Company's partners make progress
developing and commercializing their products being developed using
ENHANZE®. Halozyme is headquartered in San Diego. For more information
visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements including, without
limitation, statements concerning the possible activity, benefits
and attributes of ENHANZE®, the possible method of
action of ENHANZE®, its potential application to aid in
the dispersion and absorption of other injected therapeutic drugs
and statements concerning certain other potential benefits of
ENHANZE® including facilitating more rapid delivery and
administration of larger volumes of injectable medications through
subcutaneous delivery and potentially lowering the treatment burden
for patients. These forward-looking statements also include
statements regarding the product development and commercialization
efforts of Halozyme's ENHANZE® partner (including the
potential launch of ENHANZE® products as a result of
such efforts) and Halozyme's potential receipt of payments
associated with achievement of certain development, regulatory and
sales-based milestones, and royalties on sales of commercialized
products and the potential for such payments to extend the revenue
duration of the ENHANZE® franchise. These
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. The forward-looking statements
are typically, but not always, identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue" and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including uncertainties concerning whether
development, regulatory and sales-based milestones will be
achieved, uncertainties concerning whether collaborative products
are ultimately developed or commercialized, unexpected expenditures
and costs, unexpected results or delays in development and
regulatory review including potential delays caused by the current
COVID-19 global pandemic, unexpected regulatory approval
requirements, unexpected adverse events or patient outcomes and
competitive conditions. These and other factors that may
result in differences are discussed in greater detail in Halozyme's
most recent Annual and Quarterly Reports filed with the Securities
and Exchange Commission. Except as required by law, Halozyme
undertakes no duty to update forward-looking statements to reflect
events after the date of this release.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-therapeutics-inc-and-chugai-pharmaceutical-enter-global-collaboration-and-license-agreement-for-enhanze-technology-301509670.html
SOURCE Halozyme Therapeutics, Inc.